Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR and keeping the price target at $116.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors related to Abivax’s recent presentations and clinical trial results. The company presented late-breaking data at UEGW that highlighted obefazimod’s safety and efficacy, particularly in advanced therapy-naïve and experienced patients. The clinical remission rates observed in these subgroups were promising and aligned with investor expectations, suggesting competitive efficacy compared to existing UC therapies.
Moreover, obefazimod’s oral route of administration and its efficacy across different lines of therapy, without the safety concerns associated with JAK inhibitors, position it well for broad adoption in the treatment of ulcerative colitis (UC). The positive feedback from academic-based physicians regarding its potential use in both early and later stages of UC treatment further supports the optimism for its market potential, assuming regulatory approval. These factors collectively underpin the Buy rating assigned by Sam Slutsky.
In another report released on September 25, Citizens JMP also maintained a Buy rating on the stock with a $114.00 price target.